Program
SHR-2906
A development code. Also written as “SHR-2906 Injection”.
Its studies are mostly in Obesity, led by Jiangsu HengRui Medicine.
Furthest: phase 1, since Dec 1, 20251 company-led study, 1 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 1since Dec 1, 2025 | Dec 1, 2025 | Dec 2026phase 1 · NCT07280936 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR-2906
, phase 1, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 1, 2025First study: phase 1 study in ObesityFirst studyNCT07280936 · 76 enrolled · China
Ahead
- Dec 2026Primary completion: phase 1 study in ObesityNCT07280936
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07280936Obesity · China | 1 | Active, not recruiting | Dec 2026 | 76 |
How it is read
Names in the registry
- “SHR-2906 Injection”, 1 entry
Codes read as this program: SHR2906.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.